Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Management Team Additions
LINCOLNSHIRE, Ill. - July 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M. Adams, MS as Vice President, Human Resources. Dr. Croak-Brossman assumed this new role effective today. Ms. Adams assumed her new role effective in May 2011.
Dr. Croak-Brossman joins BioSante with over 24 years of experience in the pharmaceutical industry. She has held a variety of regulatory positions and has led operations at both a U.S. and global level. Dr. Croak-Brossman�s work experience includes positions at Boehringer Ingelheim, Pfizer and Abbott Laboratories. Importantly, while at Pfizer, Dr. Croak-Brossman was the worldwide regulatory lead for Viagra�. Her experience as a regulatory lead in the sexual dysfunction therapeutic market makes her uniquely qualified to manage regulatory projects as BioSante progresses towards the NDA submission for LibiGel� (testosterone gel). Dr. Croak-Brossman earned her MS and Ph.D. in Quantitative Genetics and Animal Breeding from Purdue University and conducted her Post-Doctoral Fellowship at Cornell University.
Ms. Adams has over 20 years of experience in the pharmaceutical industry. From 2009 through May 2011, Ms. Adams was with Lundbeck Inc. (the U.S. subsidiary of H. Lundbeck A/S based in Copenhagen, Denmark) where she most recently served as the Vice President of Human Resources. Prior to joining Lundbeck, Ms. Adams was employed by Takeda Pharmaceuticals North America from 1998 � 2009. While at Takeda, Ms. Adams held positions of increasing responsibility in both Human Resources and Sales Operations and created foundational policies and procedures to support the launch of Takeda�s North American headquarters. Ms. Adams� previous work experiences also include time at both TAP Pharmaceuticals and Abbott Laboratories. Ms. Adams earned her MS in Human Resources from Loyola University Chicago and her Senior Professional in Human Resources certification from The Human Resources Certification Institute.
"We are very pleased to have both Sandra Croak-Brossman and Patricia Adams joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante�s president and chief executive officer. "Sandy�s experience and expertise, particularly in leading Pfizer�s Viagra to an FDA approval, will be invaluable in view of the excellent progress we have made in the development of LibiGel for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. Patty has a clear vision for where HR needs to go and how to help BioSante recruit, retain and develop the best talent in the pharmaceutical industry. We remain dedicated to our objective of maximizing stockholder value and believe Sandy and Patty will be integral to this endeavor."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Monday, July 18, 2011
Consumer/ Retail Stocks; Major Oil Company to Support Comprehensive Test of YesDTC's (OTCBB:YESD) MotorBooster Engine Catalyst Product - Product Already Showing 16.5% Fuel Savings
SAN FRANCISCO - July 18, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced another significant development involving the recently announced performance test of its MotorBooster(TM) fuel catalyst formulation being conducted by the University of Alaska, Fairbanks (UAF). In addition to tests by the UAF, a major Alaskan oil exploration company has also expressed significant interest in the testing protocol and has stated its intent, assuming favorable test results of MotorBooster by the UAF, to employ one or more of the products across its entire fleet.
Recent fuel catalyst technologies have changed significantly from earlier versions and are now yielding strong results. YesDTC has already completed one highly successful test of this technology in conjunction with a leading NASCAR and Winston Cup development team that demonstrated a 16.5% reduction in fuel consumption and an even more significant reduction in hydrocarbon emissions. This additional test of MotorBooster by the University of Alaska is designed to further demonstrate the unique fuel savings and emission reduction capabilities of this proprietary engine catalyst.
Christian Kirsebom, General Manager of YesDTC commented, "This is a highly significant event for our Company. The science behind fuel catalysts has advanced meaningfully over the past few years and is beginning to attract a lot of attention within the scientific community. Our first test was very successful and we are confident this new test with the University of Alaska, Fairbanks will yield similar results. Being mindful of the revolutionary impact the MotorBooster product is showing to have on increasing fuel efficiency and decreasing emissions, something that could be a game changer for any industry using oil and gas fuels, we think its important to position the marketing of this product with overwhelming scientific evidence in support of its efficacy as we ready for a nationwide rollout over the coming months."
Mr. Kirsebom continued, "At a national average of $3.76 per gallon for regular, and $3.92 for premium, a 16% increase in fuel efficiency as demonstrated by the Company's last independent test would mean a $0.60 savings per gallon on regular and a very significant $0.63 savings on premium, while users switching from premium to regular as a result of using MotorBooster would realize even more significant savings. We believe consumers will be very interested in achieving similar results as we roll this product out into the marketplace."
As an automotive combustion catalyst that targets the consumer market, MotorBooster is designed to increase fuel economy, reduce hydrocarbon emissions and enhance engine performance. MotorBooster(TM) is a proprietary formulation tablet that users simply insert into their gas tank, upon which it dissolves into the fuel to achieve mileage, emissions and enhancement benefits, including allowing motorists to use lower octane fuels for double-savings at the pump. MotorBooster is protected under U.S. patents and has received EPA Certification to not cause engine damage.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
SAN FRANCISCO - July 18, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced another significant development involving the recently announced performance test of its MotorBooster(TM) fuel catalyst formulation being conducted by the University of Alaska, Fairbanks (UAF). In addition to tests by the UAF, a major Alaskan oil exploration company has also expressed significant interest in the testing protocol and has stated its intent, assuming favorable test results of MotorBooster by the UAF, to employ one or more of the products across its entire fleet.
Recent fuel catalyst technologies have changed significantly from earlier versions and are now yielding strong results. YesDTC has already completed one highly successful test of this technology in conjunction with a leading NASCAR and Winston Cup development team that demonstrated a 16.5% reduction in fuel consumption and an even more significant reduction in hydrocarbon emissions. This additional test of MotorBooster by the University of Alaska is designed to further demonstrate the unique fuel savings and emission reduction capabilities of this proprietary engine catalyst.
Christian Kirsebom, General Manager of YesDTC commented, "This is a highly significant event for our Company. The science behind fuel catalysts has advanced meaningfully over the past few years and is beginning to attract a lot of attention within the scientific community. Our first test was very successful and we are confident this new test with the University of Alaska, Fairbanks will yield similar results. Being mindful of the revolutionary impact the MotorBooster product is showing to have on increasing fuel efficiency and decreasing emissions, something that could be a game changer for any industry using oil and gas fuels, we think its important to position the marketing of this product with overwhelming scientific evidence in support of its efficacy as we ready for a nationwide rollout over the coming months."
Mr. Kirsebom continued, "At a national average of $3.76 per gallon for regular, and $3.92 for premium, a 16% increase in fuel efficiency as demonstrated by the Company's last independent test would mean a $0.60 savings per gallon on regular and a very significant $0.63 savings on premium, while users switching from premium to regular as a result of using MotorBooster would realize even more significant savings. We believe consumers will be very interested in achieving similar results as we roll this product out into the marketplace."
As an automotive combustion catalyst that targets the consumer market, MotorBooster is designed to increase fuel economy, reduce hydrocarbon emissions and enhance engine performance. MotorBooster(TM) is a proprietary formulation tablet that users simply insert into their gas tank, upon which it dissolves into the fuel to achieve mileage, emissions and enhancement benefits, including allowing motorists to use lower octane fuels for double-savings at the pump. MotorBooster is protected under U.S. patents and has received EPA Certification to not cause engine damage.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Oil and Gas Stocks News; American Petro-Hunter (OTCBB: AAPH) Announces Drilling Plans for 11 Horizontal Wells at North Oklahoma Project
SCOTTSDALE, AZ - July 18, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is pleased to announce updated plans regarding the Company's continued participation in a proposed field development horizontal drilling program of the Mississippi formation at the North Oklahoma Project.
Based on the commercial success of the recent NOM-1H horizontal well, the Company and working interest partners have determined that the development plan for this newly defined Mississippi oil and gas reservoir can accommodate the drilling of a minimum of 11 horizontal wells.
The drilling schedule, which includes direct offsets to the producing NOM-1H, will involve the drilling of approximately one horizontal Mississippi well every 30 to 60 days with plans to commence the program in early September. The schedule allows for a predictable time frame to drill, complete and put in requisite production facilities for both oil sales plus a gas line hook up every other month.
This aggressive drilling schedule signifies there will be well drilling, completion and potential production activity on the Ripley project leases for the remainder of 2011 and throughout 2012. In total, 12 production wells are targeted for the full development of the project.
The operator has further advised the Company that the same group of professional oil and gas contractors and engineers will be involved in all aspects of the engineering design, vertical and directional drilling of the proposed program as the group performed well above expectations on the drilling and completion of the NOM-1H well.
Company President Robert McIntosh states, "We couldn't be more pleased with the proposed engineering plans to drill 11 more horizontal wells on the Ripley leases. Our commitment to this project is indicative of how this area has become a core asset and means we aim to be very busy drilling wells in this area for the foreseeable future. The continued success of this project is poised to dictate our growth and will prove instrumental in meeting our long range production targets."
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
SCOTTSDALE, AZ - July 18, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is pleased to announce updated plans regarding the Company's continued participation in a proposed field development horizontal drilling program of the Mississippi formation at the North Oklahoma Project.
Based on the commercial success of the recent NOM-1H horizontal well, the Company and working interest partners have determined that the development plan for this newly defined Mississippi oil and gas reservoir can accommodate the drilling of a minimum of 11 horizontal wells.
The drilling schedule, which includes direct offsets to the producing NOM-1H, will involve the drilling of approximately one horizontal Mississippi well every 30 to 60 days with plans to commence the program in early September. The schedule allows for a predictable time frame to drill, complete and put in requisite production facilities for both oil sales plus a gas line hook up every other month.
This aggressive drilling schedule signifies there will be well drilling, completion and potential production activity on the Ripley project leases for the remainder of 2011 and throughout 2012. In total, 12 production wells are targeted for the full development of the project.
The operator has further advised the Company that the same group of professional oil and gas contractors and engineers will be involved in all aspects of the engineering design, vertical and directional drilling of the proposed program as the group performed well above expectations on the drilling and completion of the NOM-1H well.
Company President Robert McIntosh states, "We couldn't be more pleased with the proposed engineering plans to drill 11 more horizontal wells on the Ripley leases. Our commitment to this project is indicative of how this area has become a core asset and means we aim to be very busy drilling wells in this area for the foreseeable future. The continued success of this project is poised to dictate our growth and will prove instrumental in meeting our long range production targets."
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Friday, July 15, 2011
Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter
SAN DIEGO – July 15, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders.
To our Shareholders:
Last December, I authored a shareholder letter which referenced the viewpoint of healthcare leaders who felt a need for innovative new therapeutic strategies to evolve as escalating regulatory costs, challenges and uncertainties made it nearly impossible for small to mid-size organizations to commercialize their drug candidates. In response, we introduced the Aethlon ADAPT™ (Adaptive Dialysis-Like Affinity Platform Technology) system, as an innovative medical device platform that provides a basis to create new therapeutic devices through the convergence of affinity drug agents and plasma membrane technologies. The Aethlon ADAPT™ system provides a previously unrecognized commercialization pathway to antibody and other affinity drug developers, who should also appreciate a less onerous medical device regulatory pathway. We are already seeing evidence of our ADAPT™ system being the impetus for industry collaborations that offer new channels of early revenue generation.
On May 25th, we introduced our Aethlon ADAPT™ system to the drug industry at the C21 Life Sciences Partnering Conference. However, we had already begun to leverage our ADAPT™ system on April 1st, through a response to a government contract opportunity offered by the Defense Advanced Research Projects Agency (DARPA) entitled, "Dialysis-Like Therapeutics." Included within our response was a proposal to develop a device that would reduce the incidence of sepsis in wounded war-fighters. I am pleased to inform you that our submitted program was chosen for funding by a panel of experts assembled by DARPA. While it is an honor to be chosen to receive a contract award, I ask that you curb any assumption that we have won a contract based on information that may be published on the Internet. A contract that leads to funding of our proposed program is predicated on the successful completion of a detailed contracting process. On June 29th, we again leveraged the capabilities of our ADAPT™ system through a response to a U.S. Army initiative to create a device that would meet the objective of a program entitled "Blood Purification for Organ Failure."
The genesis of the Aethlon ADAPT™ system is our Hemopurifier®, a device that has demonstrated broad-spectrum activity against infectious viral pathogens, immunosuppressive proteins and exosomes secreted by cancer. Increasingly, exosomes are being discovered to have implications in other life-threatening diseases. Next Tuesday (July 19th), we will meet with FDA officials to discuss a proposed clinical program to support the regulatory advancement of our Hemopurifier® as a treatment countermeasure against bioterror and pandemic threats. Based on data collected from clinical programs conducted in India, we will also seek permission from the FDA to expand our treatment indications to include Hepatitis C virus (HCV). Formal FDA feedback to next week's meeting would likely occur in early fall. Should the FDA grant permission to initiate our U.S. clinical studies, we have already submitted (on May 31st of this year) a request to the Biomedical Advanced Research and Development Authority (BARDA) to fund clinical programs specific to bioterror and pandemic threats. In the meantime, we continue to advance our HCV treatment program at the Medanta Medicity Institute. As previously communicated, positive clinical outcomes from this study will lead to commercialization of our Hemopurifier® in India. Regardless of the many challenges we have confronted, we continue to advance our mission to create innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On behalf of your dedicated team at Aethlon Medical, I again thank you for your continued support and belief in our endeavors.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including consummating government contracts or grants, the FDA's willingness to allow the Company to proceed with the clinical trials proposed in the re-initiation of an Investigational Device Exemption (IDE) study, or the FDA's willingness to meet with company officials to discuss Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats, the Company's ability to conduct clinical trials in Europe or to achieve regulatory approval in Europe, the Company's ability to commercialize its Hemopurifier® in India, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO – July 15, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders.
To our Shareholders:
Last December, I authored a shareholder letter which referenced the viewpoint of healthcare leaders who felt a need for innovative new therapeutic strategies to evolve as escalating regulatory costs, challenges and uncertainties made it nearly impossible for small to mid-size organizations to commercialize their drug candidates. In response, we introduced the Aethlon ADAPT™ (Adaptive Dialysis-Like Affinity Platform Technology) system, as an innovative medical device platform that provides a basis to create new therapeutic devices through the convergence of affinity drug agents and plasma membrane technologies. The Aethlon ADAPT™ system provides a previously unrecognized commercialization pathway to antibody and other affinity drug developers, who should also appreciate a less onerous medical device regulatory pathway. We are already seeing evidence of our ADAPT™ system being the impetus for industry collaborations that offer new channels of early revenue generation.
On May 25th, we introduced our Aethlon ADAPT™ system to the drug industry at the C21 Life Sciences Partnering Conference. However, we had already begun to leverage our ADAPT™ system on April 1st, through a response to a government contract opportunity offered by the Defense Advanced Research Projects Agency (DARPA) entitled, "Dialysis-Like Therapeutics." Included within our response was a proposal to develop a device that would reduce the incidence of sepsis in wounded war-fighters. I am pleased to inform you that our submitted program was chosen for funding by a panel of experts assembled by DARPA. While it is an honor to be chosen to receive a contract award, I ask that you curb any assumption that we have won a contract based on information that may be published on the Internet. A contract that leads to funding of our proposed program is predicated on the successful completion of a detailed contracting process. On June 29th, we again leveraged the capabilities of our ADAPT™ system through a response to a U.S. Army initiative to create a device that would meet the objective of a program entitled "Blood Purification for Organ Failure."
The genesis of the Aethlon ADAPT™ system is our Hemopurifier®, a device that has demonstrated broad-spectrum activity against infectious viral pathogens, immunosuppressive proteins and exosomes secreted by cancer. Increasingly, exosomes are being discovered to have implications in other life-threatening diseases. Next Tuesday (July 19th), we will meet with FDA officials to discuss a proposed clinical program to support the regulatory advancement of our Hemopurifier® as a treatment countermeasure against bioterror and pandemic threats. Based on data collected from clinical programs conducted in India, we will also seek permission from the FDA to expand our treatment indications to include Hepatitis C virus (HCV). Formal FDA feedback to next week's meeting would likely occur in early fall. Should the FDA grant permission to initiate our U.S. clinical studies, we have already submitted (on May 31st of this year) a request to the Biomedical Advanced Research and Development Authority (BARDA) to fund clinical programs specific to bioterror and pandemic threats. In the meantime, we continue to advance our HCV treatment program at the Medanta Medicity Institute. As previously communicated, positive clinical outcomes from this study will lead to commercialization of our Hemopurifier® in India. Regardless of the many challenges we have confronted, we continue to advance our mission to create innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On behalf of your dedicated team at Aethlon Medical, I again thank you for your continued support and belief in our endeavors.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including consummating government contracts or grants, the FDA's willingness to allow the Company to proceed with the clinical trials proposed in the re-initiation of an Investigational Device Exemption (IDE) study, or the FDA's willingness to meet with company officials to discuss Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats, the Company's ability to conduct clinical trials in Europe or to achieve regulatory approval in Europe, the Company's ability to commercialize its Hemopurifier® in India, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Defense and Security Stocks; United Protection Security Group Inc. (TSX-V: UZZ) - Acquisition Closing Date re-scheduled
Edmonton, Alberta CANADA - July 15, 2011 (InvestorIdeas.com Newswire) - United Protection Security Group Inc. (TSX-V:UZZ) (UPSG or the Company), announces that the Closing Date for the acquisition of an Edmonton based Video Verification Security Systems company ("the Target"), as previously reported on June 14, 2011, has been postponed until August 31, 2011. The acquisition of the Target will be subject to the preparation and execution of a Definitive Purchase Agreement, as well as obtaining the approval of the board of directors and the TSX Venture Exchange, prior to that date.
Stock Awareness Activities
To find out more about United Protection Security Group Inc. (TSX-V: UZZ), visit our website at www.unitedprotection.com. To join the 'request for information', go to the web page www.unitedprotection.com and click the tab 'request information' and follow the prompts.
For additional investor and media relations inquiries contact:
Fredy Ramsoondar CEO and Director
Email: fredy.ramsoondar@unitedprotection.com
Tel: 780-465-8101
Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, are forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks related to business development and retention, and risks related to the current economic and credit conditions. As a result, actual results may vary materially from those described in the forward-looking statements.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
United Protection Security Group Inc. (TSX - V: UZZ)
#212, 8711A - 50th Street, Edmonton, Alberta T6B 1E7
Telephone (780) 465-8101
To view this press release as a web page, click onto the link below:
www.usetdas.com/PR/unitedprotection15072011.htm
Source: United Protection Security Group Inc. (TSX-V: UZZ) http://www.unitedprotection.com
Maximum News Dissemination by Filing Services Canada Inc. http://www.usetdas.com
Disclosure: UZZ is a paid advertising client on Investorideas.com and our defense portals.
Edmonton, Alberta CANADA - July 15, 2011 (InvestorIdeas.com Newswire) - United Protection Security Group Inc. (TSX-V:UZZ) (UPSG or the Company), announces that the Closing Date for the acquisition of an Edmonton based Video Verification Security Systems company ("the Target"), as previously reported on June 14, 2011, has been postponed until August 31, 2011. The acquisition of the Target will be subject to the preparation and execution of a Definitive Purchase Agreement, as well as obtaining the approval of the board of directors and the TSX Venture Exchange, prior to that date.
Stock Awareness Activities
To find out more about United Protection Security Group Inc. (TSX-V: UZZ), visit our website at www.unitedprotection.com. To join the 'request for information', go to the web page www.unitedprotection.com and click the tab 'request information' and follow the prompts.
For additional investor and media relations inquiries contact:
Fredy Ramsoondar CEO and Director
Email: fredy.ramsoondar@unitedprotection.com
Tel: 780-465-8101
Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, are forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks related to business development and retention, and risks related to the current economic and credit conditions. As a result, actual results may vary materially from those described in the forward-looking statements.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
United Protection Security Group Inc. (TSX - V: UZZ)
#212, 8711A - 50th Street, Edmonton, Alberta T6B 1E7
Telephone (780) 465-8101
To view this press release as a web page, click onto the link below:
www.usetdas.com/PR/unitedprotection15072011.htm
Source: United Protection Security Group Inc. (TSX-V: UZZ) http://www.unitedprotection.com
Maximum News Dissemination by Filing Services Canada Inc. http://www.usetdas.com
Disclosure: UZZ is a paid advertising client on Investorideas.com and our defense portals.
Interview with Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), Discusses the Potential of Future Partners or Acquisition
Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals, as industry buzz builds on talk of partners or acquisition with value up to $1 Billion.
As BioSante's lead product LibiGel ® (transdermal testosterone gel), for the treatment of female sexual dysfunction gets closer to market, the company is now on the radar as a biotech company to watch.
BioSante Pharmaceuticals Interview
Q: Investorideas.com
Stephen, there is an old saying in the market, that the trading tells the story. The activity and interest in your stock is building from both analysts and retail investors. Can you give us some insight to the key points of the recent analyst coverage and what the industry is saying about your company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have been in development of LibiGel for quite a number of years. Finally the finish line is in site. We have completed enrollment of women into our three LibiGel Phase III clinical studies and efficacy data should be available in the fourth quarter of this year. Safety data should be available in the third quarter of 2012 and our objective is to submit the LibiGel new drug application (NDA) to the FDA in the fourth quarter of 2012. All of these dates are near-term opportunities in the biotech/pharma world. Analysts and investors are taking note of the progress we have made with LibiGel.
Q: Investorideas.com
Can you discuss the potential dollar value for a female sexual dysfunction drug hitting the market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the market for a drug for female sexual dysfunction is potentially bigger than the market for erectile dysfunction drugs, a $2 billion market if the U.S., and male testosterone, a $1.3 billion market in the U.S. Our belief is based on current off-label use of products to treat female sexual dysfunction as well as publications that indicate the potential size of the market for treatment of female sexual dysfunction. It has been over 13 years since Viagra was approved and we believe strongly that women deserve an FDA-approved therapeutic choice for their sexual health issues.
Q: Investorideas.com
With LibiGel ® getting closer to market, how will the process of potential partners or acquisition play out in the pharma industry?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our focus is on completing the LibiGel Phase III clinical work and submitting an NDA in 2012. Our LibiGel partnering strategy from the beginning has been and remains to develop LibiGel as far as we can since we believe the best way to maximize our stockholder value is to bring LibiGel to the latest stage of product development and regulatory status possible. Although we would entertain a license/partnership at this time, we believe the value of LibiGel will increase as new efficacy and safety data become available and these data will be available beginning in the coming months.
Q: Investorideas.com
With other players abandoning the female sexual dysfunction market, your company stayed through the long process and is now postured to be first to market. How significant is it that you have no current competition?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
As stated before we believe the market for female sexual dysfunction is significant and we would welcome other companies to develop product for this market. Having said that, today LibiGel is the only product in Phase III clinical development in the world. Assuming positive safety and efficacy data, we believe LibiGel will be the first product approved by the FDA for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder. In our primary market research with prescribing physicians, they tell us that there is a great need for an FDA-approved product and that they are dissatisfied with their choices for off-label use. If and when LibiGel is approved we believe it will be a very successful product and result in a very attractive choice for prescribers and women in need, and continued increasing value for our stockholders.
About LibiGel ®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that have enrolled over 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials, which have completed enrollment, are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued 4,000 women-years of exposure. The study will continue for a total of five years, however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the second half of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals, as industry buzz builds on talk of partners or acquisition with value up to $1 Billion.
As BioSante's lead product LibiGel ® (transdermal testosterone gel), for the treatment of female sexual dysfunction gets closer to market, the company is now on the radar as a biotech company to watch.
BioSante Pharmaceuticals Interview
Q: Investorideas.com
Stephen, there is an old saying in the market, that the trading tells the story. The activity and interest in your stock is building from both analysts and retail investors. Can you give us some insight to the key points of the recent analyst coverage and what the industry is saying about your company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have been in development of LibiGel for quite a number of years. Finally the finish line is in site. We have completed enrollment of women into our three LibiGel Phase III clinical studies and efficacy data should be available in the fourth quarter of this year. Safety data should be available in the third quarter of 2012 and our objective is to submit the LibiGel new drug application (NDA) to the FDA in the fourth quarter of 2012. All of these dates are near-term opportunities in the biotech/pharma world. Analysts and investors are taking note of the progress we have made with LibiGel.
Q: Investorideas.com
Can you discuss the potential dollar value for a female sexual dysfunction drug hitting the market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the market for a drug for female sexual dysfunction is potentially bigger than the market for erectile dysfunction drugs, a $2 billion market if the U.S., and male testosterone, a $1.3 billion market in the U.S. Our belief is based on current off-label use of products to treat female sexual dysfunction as well as publications that indicate the potential size of the market for treatment of female sexual dysfunction. It has been over 13 years since Viagra was approved and we believe strongly that women deserve an FDA-approved therapeutic choice for their sexual health issues.
Q: Investorideas.com
With LibiGel ® getting closer to market, how will the process of potential partners or acquisition play out in the pharma industry?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our focus is on completing the LibiGel Phase III clinical work and submitting an NDA in 2012. Our LibiGel partnering strategy from the beginning has been and remains to develop LibiGel as far as we can since we believe the best way to maximize our stockholder value is to bring LibiGel to the latest stage of product development and regulatory status possible. Although we would entertain a license/partnership at this time, we believe the value of LibiGel will increase as new efficacy and safety data become available and these data will be available beginning in the coming months.
Q: Investorideas.com
With other players abandoning the female sexual dysfunction market, your company stayed through the long process and is now postured to be first to market. How significant is it that you have no current competition?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
As stated before we believe the market for female sexual dysfunction is significant and we would welcome other companies to develop product for this market. Having said that, today LibiGel is the only product in Phase III clinical development in the world. Assuming positive safety and efficacy data, we believe LibiGel will be the first product approved by the FDA for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder. In our primary market research with prescribing physicians, they tell us that there is a great need for an FDA-approved product and that they are dissatisfied with their choices for off-label use. If and when LibiGel is approved we believe it will be a very successful product and result in a very attractive choice for prescribers and women in need, and continued increasing value for our stockholders.
About LibiGel ®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that have enrolled over 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials, which have completed enrollment, are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued 4,000 women-years of exposure. The study will continue for a total of five years, however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the second half of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
POINT ROBERTS - July 15, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 14, 2011. Omega Navigation Enterprises, Inc topped the gainer list, rising about 46% on Thursday.
Omega Navigation Enterprises, Inc. (NASDAQ:ONAV) was the biggest gaineron Nasdaq and soared 0.135 (45.81%) to $0.43 following it announced that, in connection with its Chapter 11 proceedings in Houston, Texas, the Court has granted all of the interim relief that Omega requested.
Icagen, Inc. (NASDAQ:ICGN) also rose 1.85 (30.58%) to $7.90 on no news. The stock also made a new 52-week high of $8.20 on Thursday with more than 5.50 million shares compared to its average volume of 490K shares. The company has a market capitalization of $59.24 million.
Universal Forest Products, Inc. (NASDAQ:UFPI) climbed 5.06 (21.02%) to $29.13 after the company said that its revenue during the second quarter 2011 fell 14.80% year over year to $544.1 million. The company said it won’t resume giving forecasts because of challenging economic conditions. Analysts were estimating the company to report revenue of $564 million.
Gulf Resources, Inc. (NASDAQ:GURE) surged 0.42 (13.00%) to $3.65 it announced that its Chairman, Ming Yang and his family will hold their shares for the next three years and confirmed that Gulf Resources maintains 100% ownership of its two PRC subsidiaries Shouguang City Haoyuan Chemical Ltd. Co. ("SCHC") and Shouguang Yuxin Chemical Industry Co., Ltd. ("SYCI")
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Thursday, July 14, 2011
Iron Ore Stocks Trading Alert; LCY, TRKP, FXPO, FEO
TurkPower Corporation (OTCBB: TRKP) traded up to $0.35 during the day. On Jul 05, 2011, the company announced the purchase of 50.09% working interest in Maksor Madencilik Sanayi Ve Ticaret Anonim Sirketi (hereafter "Maksor"), the 100% private owner of the Kuluncak iron ore project in Turkey.
In a recent Q&A, Ryan E. Hart, Executive Chairman of TurkPower Corporation (OTCBB: TRKP), noted “ With the purchase of controlling interest in the operational Kuluncak iron ore mine, TurkPower is taking its first step toward its goal of becoming a leading junior mining company in Turkey. The purchase adds a tangible and operational asset to the Company's balance sheet and leads to expected profitability in 2011. It also gives the Company leverage and credibility for future mining ventures and acquisitions in the booming mining industry of Turkey.”
Legacy Iron Ore (ASX: LCY) has progressed initial discussions with National Mineral Development Corporation Limited (NMDC), a Government of India state owned public enterprise to meetings in Perth with Legacy.
In June, Legacy defined a maiden JORC compliant Inferred Resource at Mt Bevan Iron Ore project of 617 million tonnes at 32.1% Iron.
Shares of LCY soared 11.70% to $0.105.
FERREXPO (LSE: FXPO.L) closed with a gain of 4.28% to $470.70. Last week, the company said that iron ore production in the second quarter fell 2.5% from the year earlier, taking output for the year down 2.1%.
OCEANIC IRON ORE CORP (TSXV: FEO.V ) gained over 6% to $0.44 after it hosted a total of 9 institutional analysts and shareholders at the Company's inaugural site visit, which took place on July 6 and 7th, 2011.
Iron Ore Stocks Snapshot:
- Cazaly Resources Limited (ASX: CAZ) surged 2.86% to $0.36.
- Eastern Iron Limited (ASX: EFE) ended the day with a gain of 30% at $0.13.
- Mechel OAO (ADR) (NYSE:MTL) jumped 3.84% to $24.62.
- Australasian Resources Ltd. (ASX: ARH) ended the day with a gain of 2.38% to $0.215.
- TurkPower Corporation (OTCBB: TRKP)
TurkPower Corporation (OTCBB:TRKP) is a Turkish-American junior mining company that is acquiring controlling ownership in an operational iron ore mine and several mining projects under development in Turkey. TurkPower's sole focus is on the booming Turkish mining industry, where it aims to become a leader in developing, operating and owning base metal mines by acquiring and consolidating operational mines with proven reserves, utilizing economies of scale to increase returns as well as developing new mining assets. TurkPower's board of
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/TRKP/
Sign up for news on TRKP and other mining stocks
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. TRKP is a paid advertising client ( three thousand five hundred per month, 150,000 144 shares) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com
Energy Stock News; Osage (OTCBB: OEDV), Slawson, and USEDC Continue to Expand Horizontal Mississippian Project
SAN DIEGO, CA - July 14, 2011 (Investorideas.com energystocks newswire) - Osage Exploration and Development, Inc. (OTCBB: OEDV) along with its partners, Slawson Exploration Company, Inc. and U.S. Energy Development Corporation are pleased to announce that their Nemaha Ridge Mississippian prospect has now reached 12,000 net mineral acres, an increase from 10,000 net acres announced in late May 2011.
"The growth of the horizontal Mississippian play in Oklahoma is accelerating at an amazing rate. Devon Energy is the latest major Oklahoma oil company to announce the acquisition of a significant land position prospective for the Mississippian and the Woodford Shale. With SandRidge Energy, Inc., Chesapeake Energy Corporation, and Range Resources already extensively involved in the horizontal Mississippian, it is beginning to look unanimous. The finest oil companies in Oklahoma have all chosen to participate in what appears to be one of the most economic onshore oil plays that we have seen in decades. At Osage, we feel that our scientific work has been substantially validated simply by the presence of these industry leaders in our focus play," stated Kim Bradford, President and CEO.
"With over 200 successful horizontal Mississippian wells already drilled in Oklahoma, the focus in this play is going to rapidly shift to execution and cost control. In that regard, with Slawson Exploration and U.S. Energy Development Corp., we have two of the very best in our corner. We are confident that the Nemaha Ridge will be a highly productive area and that we can efficiently extract the minerals, given our operating partner's horizontal success in the Bakken and other basins," stated Greg Franklin, VP Exploration.
We have posted an investor presentation on our website concurrent with this news release. Please click on the link below to view the presentation:
http://www.osageexploration.com
For a visual depiction of the horizontal drilling technique that will be utilized in the Nemaha Ridge project, click on the video link below:
http://www.osageexploration.com/video/index.htm
About Osage Exploration and Development, Inc.
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogot�, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
About Slawson Exploration Company, Inc.
Headquartered in Wichita, KS, with regional offices in Denver, Houston, and Oklahoma City, Slawson was founded in 1957. http://www.slawsoncompanies.com/exploration.html
About U.S. Energy Development Corporation
U.S. Energy Development Corporation was formed in 1980 as a successor to Oilmark & Company, Inc., founded in 1978. The company has consistently been ranked among the Top 50 Independent Oil & Natural Gas Drillers in the UnitedStates and is one of the largest drillers in both New York and Pennsylvania. Since 1980, U.S. Energy has acted as operator with respect to the drilling of more than 2,500 wells. www.usenergydevcorp.com
Safe Harbor Statement
The information in this release includes certain forward-looking statements as defined by the Securities and Exchange Commission that are based on assumptions that in the future may prove not to have been accurate. Those statements and Osage Exploration and Development, Inc. are subject to a number of risks, including production variances from expectations, volatility of product prices, inability to raise sufficient capital to fund its operations, environmental risks, competition, government regulation, and the ability of the Company to execute its business strategy, among others.
Contact:
Osage Exploration and Development, Inc.
Kim Bradford, President and CEO
Phone: 619-677-3956
Fax: 619-677-3964
kbradford@osageexploration.com
www.osageexploration.com
or
Standard & Poor's Customer Contact:
Richard Albanese, 212-438-3647
richard_albanese@sandp.com
or
Media Relations Contact:
Michael Privitera, 212-438-6679
michael_privitera@sandp.com
SAN DIEGO, CA - July 14, 2011 (Investorideas.com energy
"The growth of the horizontal Mississippian play in Oklahoma is accelerating at an amazing rate. Devon Energy is the latest major Oklahoma oil company to announce the acquisition of a significant land position prospective for the Mississippian and the Woodford Shale. With SandRidge Energy, Inc., Chesapeake Energy Corporation, and Range Resources already extensively involved in the horizontal Mississippian, it is beginning to look unanimous. The finest oil companies in Oklahoma have all chosen to participate in what appears to be one of the most economic onshore oil plays that we have seen in decades. At Osage, we feel that our scientific work has been substantially validated simply by the presence of these industry leaders in our focus play," stated Kim Bradford, President and CEO.
"With over 200 successful horizontal Mississippian wells already drilled in Oklahoma, the focus in this play is going to rapidly shift to execution and cost control. In that regard, with Slawson Exploration and U.S. Energy Development Corp., we have two of the very best in our corner. We are confident that the Nemaha Ridge will be a highly productive area and that we can efficiently extract the minerals, given our operating partner's horizontal success in the Bakken and other basins," stated Greg Franklin, VP Exploration.
We have posted an investor presentation on our website concurrent with this news release. Please click on the link below to view the presentation:
http://www.osageexploration.com
For a visual depiction of the horizontal drilling technique that will be utilized in the Nemaha Ridge project, click on the video link below:
http://www.osageexploration.com/video/index.htm
About Osage Exploration and Development, Inc.
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogot�, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
About Slawson Exploration Company, Inc.
Headquartered in Wichita, KS, with regional offices in Denver, Houston, and Oklahoma City, Slawson was founded in 1957. http://www.slawsoncompanies.com/exploration.html
About U.S. Energy Development Corporation
U.S. Energy Development Corporation was formed in 1980 as a successor to Oilmark & Company, Inc., founded in 1978. The company has consistently been ranked among the Top 50 Independent Oil & Natural Gas Drillers in the United
Safe Harbor Statement
The information in this release includes certain forward-looking statements as defined by the Securities and Exchange Commission that are based on assumptions that in the future may prove not to have been accurate. Those statements and Osage Exploration and Development, Inc. are subject to a number of risks, including production variances from expectations, volatility of product prices, inability to raise sufficient capital to fund its operations, environmental risks, competition, government regulation, and the ability of the Company to execute its business strategy, among others.
Contact:
Osage Exploration and Development, Inc.
Kim Bradford, President and CEO
Phone: 619-677-3956
Fax: 619-677-3964
kbradford@osageexploration.com
www.osageexploration.com
or
Standard & Poor's Customer Contact:
Richard Albanese, 212-438-3647
richard_albanese@sandp.com
or
Media Relations Contact:
Michael Privitera, 212-438-6679
michael_privitera@sandp.com
Osage Exploration and Development, Inc. (OEDV.OB) is a showcase oil and gas stock on Investorideas.com
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure : (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure : (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
NASDAQ Top Winners July 13th: ONAV, CLNE, CHCI, ZAGG
POINT ROBERTS - July 14, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 13, 2011, with Omega Navigation Enterprises, Inc topping the gainer list, rising about 73.53% on Wednesday.
Omega Navigation Enterprises, Inc. (NASDAQ:ONAV) was the biggest gaineron Nasdaq, moving up 0.125 (73.53%) to $0.295 following a 50% fall in the past week as the company had filed for bankruptcy in the U.S. after failing to reach an agreement with lenders to restructure debt.
Clean Energy Fuels Corp. (NASDAQ:CLNE) also rose 1.93 (12.80%) to $17.01 after analyst at Bank of America Merrill Lynch upgraded their rating on the stock to buy from underperform as the company continues to draw praise from Wall Street from a $150 million convertible debt investment from Cheseapeake Energy Corp. (NYSE: CHK) earlier this week.
Comstock Homebuilding Companies, Inc. (NASDAQ:CHCI) climbed 0.12 (10.52%) to $1.26 after the company announced that it has formed a strategic alliance with SunBridge Capital Management, LLC ("SunBridge"), a private investment management firm supported by the Bainum family, a prominent Washington, DC family with investment interests that include Choice Hotels International.
Zagg Inc (NASDAQ:ZAGG) surged 1.20 (9.12%) to $14.36 after analyst at Ladenburg Thalmann started a coverage on the stock with a Buy rating and set a price target of $20, citing ongoing consumer demand for smartphones and tablet PCs is fueling demand for accessories, providing a bigger opportunity for the company.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewableenergy , water and energy stocks .
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
POINT ROBERTS - July 14, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 13, 2011, with Omega Navigation Enterprises, Inc topping the gainer list, rising about 73.53% on Wednesday.
Omega Navigation Enterprises, Inc. (NASDAQ:ONAV) was the biggest gaineron Nasdaq, moving up 0.125 (73.53%) to $0.295 following a 50% fall in the past week as the company had filed for bankruptcy in the U.S. after failing to reach an agreement with lenders to restructure debt.
Clean Energy Fuels Corp. (NASDAQ:CLNE) also rose 1.93 (12.80%) to $17.01 after analyst at Bank of America Merrill Lynch upgraded their rating on the stock to buy from underperform as the company continues to draw praise from Wall Street from a $150 million convertible debt investment from Cheseapeake Energy Corp. (NYSE: CHK) earlier this week.
Comstock Homebuilding Companies, Inc. (NASDAQ:CHCI) climbed 0.12 (10.52%) to $1.26 after the company announced that it has formed a strategic alliance with SunBridge Capital Management, LLC ("SunBridge"), a private investment management firm supported by the Bainum family, a prominent Washington, DC family with investment interests that include Choice Hotels International.
Zagg Inc (NASDAQ:ZAGG) surged 1.20 (9.12%) to $14.36 after analyst at Ladenburg Thalmann started a coverage on the stock with a Buy rating and set a price target of $20, citing ongoing consumer demand for smartphones and tablet PCs is fueling demand for accessories, providing a bigger opportunity for the company.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Wednesday, July 13, 2011
Oil and Gas Stocks News; (OTCBB: AAPH) Oklahoma Experiencing Resurgence in Oil Drilling
NEW YORK, NY � July 13, 2011 (Investorideas.com energy newswire) - American Petro-Hunter (PINKSHEETS: AAPH) has been making progress at the Company's Northern Oklahoma property recently announcing its first oil and gas sale shortly after the project went into production.
Oklahoma has seen a sharp increase in the amount of rigs within its borders, especially since the first half of 2010. According to a June 2011 Report by Headwaters Economics (http://headwaterseconomics.org/energy/western/rig-activity/) horizontal drilling, a technique employed by American Petro-Hunter, has been one of the leading reasons for the growth and development as more oil and gas is able to be recovered from what used to be unconventional plays.
American Petro-Hunter is following some big players in oil and gas with its location and techniques. Range Resources Corp. (NYSE: RRC), Continental Resources, Inc. (NYSE: CLP) and Forest Oil Corp. (NYSE: FST) all have substantial interest in the fields in Oklahoma near American Petro-Hunter and are employing similar drilling techniques for oil and gas recovery.
For more information, please visit www.americanpetrohunter.com
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid OTC Report twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
NEW YORK, NY � July 13, 2011 (Investorideas.com energy newswire) - American Petro-Hunter (PINKSHEETS: AAPH) has been making progress at the Company's Northern Oklahoma property recently announcing its first oil and gas sale shortly after the project went into production.
Oklahoma has seen a sharp increase in the amount of rigs within its borders, especially since the first half of 2010. According to a June 2011 Report by Headwaters Economics (http://headwaterseconomics.org/energy/western/rig-activity/) horizontal drilling, a technique employed by American Petro-Hunter, has been one of the leading reasons for the growth and development as more oil and gas is able to be recovered from what used to be unconventional plays.
American Petro-Hunter is following some big players in oil and gas with its location and techniques. Range Resources Corp. (NYSE: RRC), Continental Resources, Inc. (NYSE: CLP) and Forest Oil Corp. (NYSE: FST) all have substantial interest in the fields in Oklahoma near American Petro-Hunter and are employing similar drilling techniques for oil and gas recovery.
For more information, please visit www.americanpetrohunter.com
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid OTC Report twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Frankfurt Green Energy Stocks Investor Alert; (GZA.F), (PS4.F), (CYW.F), (TSX: APV, Frankfurt: A3T), (QCE)
PointRoberts , WA - July 13, 2011 - Investorideas.com, a leader in cleantech investor research issues an investor snapshot for cleantech companies trading on the Frankfurt Stock Exchange.
Wind company, CITY WINDMILLS (CYW.F ) fell 2.50% to close at $1.02.Recently, the company announced that Roland J. Bopp joined the company, effective May 23rd 2011, as Chief Executive Officer of its U.S. subsidiary, City Windmills Inc. Mr. Bopp is also a member of the Advisory Board of the parent organization. The Company is posturing to be one few players in the green energy/green advertising space in global markets.
Algae. Tec (ASX:AEB.AX; Frankfurt: GZA.F) closed with a gain of 0.005 (1.30%) to $0.369. Recently, the company had formed a collaboration contract with the Manildra Group to construct a demonstration-scale algae production facility at its 100 MMgy ethanol plant in Nowra, Australia. According to Algae.Tec Executive Chairman Roger Stroud, the project could be operational by the first quarter of 2012.
Bitterfeld-Wolfen (Germany), 11 July 2011 - Q-Cells, (QCE; ISIN DE0005558662) one of the world’s largest photovoltaic companies, has been issued a full notice to proceed with construction activities of a 10 Megawatt project as final part of a combined 60 Megawatt project in Ontario, Canada. Q-Cells will implement this project on a turn-key basis for Starwood Energy Group Global, LLC, and a private investment firm focused on energy infrastructure projects.
Phoenix Solar AG (PS4.F) closed with a loss of 0.68 (-3.87%) to $16.90. Today, the company said that it was selected by solarcomplex, a regional supplier of renewable energies in the Lake Constance region of Germany, to act as the EPC contractor for the 4.7MW power plant being built in Bodman-Ludwigshafen, Germany. The project will be developed on around .49 miles of land on both sides of the railway tracks between Stockach to Radolfzell.
ARISE Technologies Corporation (TSX: APV and Frankfurt: A3T), a leader in high-performance, high-quality, cost-effective solar technology, announced last week that its Systems Division has been awarded a contract to supply a 70 kilowatt ("kW") photovoltaic ("PV") rooftop solar system to the University of Waterloo's newly expanded Faculty of Environment building, named ENV3.
Frankfurt Cleantech Stocks Sector Trading Snapshot
City Windmills © was founded in early 2010 and has carried along its idea of building an efficient, enduring and cheap windmill, adapted for home use, for industrial level use and for larger sized wind farms. With City Windmills © and the low cost of production per kWh, any home can afford electricity at grid parity costs.
Several steps of developments allowed the City Windmill © system to evolve from producing energy at 0, 12 € (0, 14 US$) per kWh, then at 0, 09 € (0, 11 US$) per kWh and finally at 0,065 € (0, 08 US$) per kWh. This production cost, while amortizing the price of a City Windmill © over a period of 20 years (as for other power producing plants), is competitive with every other energy source. And this is achieved without any subsidies. In an unsubsidized environment, the payback can be as short as 4.5 years.
The company is targeting the $20 Billion outdoor advertising industry with a new concept in green outdoor advertising, combining clean energy technology and advertising.
City Windmills, Ltd. (CYW.F) is a company in the development phase, with the design, development and marketing of revolutionary small wind turbine systems clean flachblättrigen deals. The business model of Wind Mills City focuses on revenue generation from the production of clean energy from small wind turbines, along with advertising revenue. More info http://www.citywindmills.com/en/
Visit the profile for City Windmills, Ltd. (CYW.F)
http://www.investorideas.com/CO/CYW
View the company’s presentation:
http://www.investorideas.com/CO/CYW/City-Windmills-Presentation-051811.pdf
CONTACT:
Sean Kelly, Chief Financial Officer
City Wind Mills, Ltd.
+41 22 310 8603
sean.kelly@citywindmills.com
Research other wind stocks with the renewable energy stocks directory
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewableenergy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news http://www.investorideas.com/Resources/Newsletter.asp
Follow our Renewable Energy Stocks Blog onFacebook.com http://www.facebook.com/renewableenergystocks
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Learn more: Disclosure - compensation :City Windmills, Ltd. (CYW.F) 0 three thousand five hundred, plus five thousand shares per month as green showcase company .
www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
For more information contact:
D Van Zant 800.665.0411, Email: dawn@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com, City Windmills
Point
Wind company, CITY WINDMILLS (CYW.F ) fell 2.50% to close at $1.02.Recently, the company announced that Roland J. Bopp joined the company, effective May 23rd 2011, as Chief Executive Officer of its U.S. subsidiary, City Windmills Inc. Mr. Bopp is also a member of the Advisory Board of the parent organization. The Company is posturing to be one few players in the green energy/green advertising space in global markets.
Algae. Tec (ASX:AEB.AX; Frankfurt: GZA.F) closed with a gain of 0.005 (1.30%) to $0.369. Recently, the company had formed a collaboration contract with the Manildra Group to construct a demonstration-scale algae production facility at its 100 MMgy ethanol plant in Nowra, Australia. According to Algae.Tec Executive Chairman Roger Stroud, the project could be operational by the first quarter of 2012.
Bitterfeld-Wolfen (Germany), 11 July 2011 - Q-Cells, (QCE; ISIN DE0005558662) one of the world’s largest photovoltaic companies, has been issued a full notice to proceed with construction activities of a 10 Megawatt project as final part of a combined 60 Megawatt project in Ontario, Canada. Q-Cells will implement this project on a turn-key basis for Starwood Energy Group Global, LLC, and a private investment firm focused on energy infrastructure projects.
Phoenix Solar AG (PS4.F) closed with a loss of 0.68 (-3.87%) to $16.90. Today, the company said that it was selected by solarcomplex, a regional supplier of renewable energies in the Lake Constance region of Germany, to act as the EPC contractor for the 4.7MW power plant being built in Bodman-Ludwigshafen, Germany. The project will be developed on around .49 miles of land on both sides of the railway tracks between Stockach to Radolfzell.
ARISE Technologies Corporation (TSX: APV and Frankfurt: A3T), a leader in high-performance, high-quality, cost-effective solar technology, announced last week that its Systems Division has been awarded a contract to supply a 70 kilowatt ("kW") photovoltaic ("PV") rooftop solar system to the University of Waterloo's newly expanded Faculty of Environment building, named ENV3.
Frankfurt Cleantech Stocks Sector Trading Snapshot
- Solarvalue AG (SV7.F) shares ended the day at $0.43.
- 3Power Energy Group ( PSD.F) fell 0.88% to $0.565.
- KSB AG (ETR:KSB) fell 4.70 (-0.82%) to $565.30.
City Windmills © was founded in early 2010 and has carried along its idea of building an efficient, enduring and cheap windmill, adapted for home use, for industrial level use and for larger sized wind farms. With City Windmills © and the low cost of production per kWh, any home can afford electricity at grid parity costs.
Several steps of developments allowed the City Windmill © system to evolve from producing energy at 0, 12 € (0, 14 US$) per kWh, then at 0, 09 € (0, 11 US$) per kWh and finally at 0,065 € (0, 08 US$) per kWh. This production cost, while amortizing the price of a City Windmill © over a period of 20 years (as for other power producing plants), is competitive with every other energy source. And this is achieved without any subsidies. In an unsubsidized environment, the payback can be as short as 4.5 years.
The company is targeting the $20 Billion outdoor advertising industry with a new concept in green outdoor advertising, combining clean energy technology and advertising.
City Windmills, Ltd. (CYW.F) is a company in the development phase, with the design, development and marketing of revolutionary small wind turbine systems clean flachblättrigen deals. The business model of Wind Mills City focuses on revenue generation from the production of clean energy from small wind turbines, along with advertising revenue. More info http://www.citywindmills.com/en/
Visit the profile for City Windmills, Ltd. (CYW.F)
http://www.investorideas.com/CO/CYW
View the company’s presentation:
http://www.investorideas.com/CO/CYW/City-Windmills-Presentation-051811.pdf
CONTACT:
Sean Kelly, Chief Financial Officer
City Wind Mills, Ltd.
+41 22 310 8603
sean.kelly@citywindmills.com
Research other wind stocks with the renewable energy stocks directory
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news http://www.investorideas.com/Resources/Newsletter.asp
Follow our Renewable Energy Stocks Blog onFacebook.com http://www.facebook.com/renewableenergystocks
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Learn more: Disclosure - compensation :City Windmills, Ltd. (CYW.F) 0 three thousand five hundred, plus five thousand shares per month as green showcase company .
www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
For more information contact:
D Van Zant 800.665.0411, Email: dawn@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com, City Windmills
NASDAQ Top Percentage Gainers: CDTI, RADS, CLNE, WPRT
Clean Diesel Technologies, Inc. (NASDAQ:CDTI) Biggest Gainer
POINT ROBERTS, July 13, 2011 - www.InvestorIdeas.com, a global investor research portal
for independent investors, reports on top percentage gainers on the NASDAQ for July 12, 2011.
Clean Diesel Technologies, Inc topped the gainer list, rising about 60% on Tuesday.
Clean Diesel Technologies, Inc. (NASDAQ:CDTI) was the biggest gainer on Nasdaq ,soaring
2.51 (59.62%) to $6.72 after analysts at Capital Research started coverage on the stock with a
buy rating. Analysts said that prospects for improving conditions in the diesel retrofit business
would lead to increase in revenue.
Radiant Systems, Inc. (NASDAQ:RADS) also rose 6.54 (30.49%) to $27.99 after NCR
Corp.(NCR) reached an agreement to buy the company for $1.2 billion in cash.
Clean Energy Fuels Corp. (NASDAQ:CLNE) climbed 1.96 (14.94%) to $15.08 after
Chesapeake Energy announced on Tuesday that it would invest $150 million in Clean Energy to
help fund the building of new liquefied natural gas fueling stations for trucks.
Westport Innovations Inc. (USA) (NASDAQ:WPRT) surged 2.08 (8.59%) to $26.30 following
Chesapeake, which produces natural gas, announced Monday that it would spend $1 billion over
the next decade to build natural gas fueling stations and other infrastructure and innovations
that would encourage the use of natural gas. Jefferies analyst Laurence Alexander said the
announcement was "incrementally positive" for Westport.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://
www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas – Research energy stocks, mining, agriculture stocks,
cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive
subscriber-only eleven stock directories in leading sectors including renewable
energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors
we cover include; cleantech and renewable energy stocks, biotech stocks,
mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech,
agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as
an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we
offer no guarantees as to the accuracy of information presented. All Information relating to featured
companies is sourced from public documents and/ or the company and is not the opinion of our web sites.
This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Clean Diesel Technologies, Inc. (NASDAQ:CDTI) Biggest Gainer
POINT ROBERTS, July 13, 2011 - www.InvestorIdeas.com, a global investor research portal
for independent investors, reports on top percentage gainers on the NASDAQ for July 12, 2011.
Clean Diesel Technologies, Inc topped the gainer list, rising about 60% on Tuesday.
Clean Diesel Technologies, Inc. (NASDAQ:CDTI) was the biggest gainer on Nasdaq ,soaring
2.51 (59.62%) to $6.72 after analysts at Capital Research started coverage on the stock with a
buy rating. Analysts said that prospects for improving conditions in the diesel retrofit business
would lead to increase in revenue.
Radiant Systems, Inc. (NASDAQ:RADS) also rose 6.54 (30.49%) to $27.99 after NCR
Corp.(NCR) reached an agreement to buy the company for $1.2 billion in cash.
Clean Energy Fuels Corp. (NASDAQ:CLNE) climbed 1.96 (14.94%) to $15.08 after
Chesapeake Energy announced on Tuesday that it would invest $150 million in Clean Energy to
help fund the building of new liquefied natural gas fueling stations for trucks.
Westport Innovations Inc. (USA) (NASDAQ:WPRT) surged 2.08 (8.59%) to $26.30 following
Chesapeake, which produces natural gas, announced Monday that it would spend $1 billion over
the next decade to build natural gas fueling stations and other infrastructure and innovations
that would encourage the use of natural gas. Jefferies analyst Laurence Alexander said the
announcement was "incrementally positive" for Westport.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://
www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas – Research energy stocks, mining, agriculture stocks,
cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive
subscriber-only eleven stock directories in leading sectors including renewable
energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors
we cover include; cleantech and renewable energy stocks, biotech stocks,
mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech,
agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as
an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we
offer no guarantees as to the accuracy of information presented. All Information relating to featured
companies is sourced from public documents and/ or the company and is not the opinion of our web sites.
This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Subscribe to:
Posts (Atom)